GLP‑1 drugs may fight addiction across every major substance, according to a study of 600,000 people

medicalxpress - A patient of mine, a veteran who had tried to quit smoking for over a decade, told me that after he started a GLP-1 drug for his diabetes, he lost interest in cigarettes. He didn't use a patch. He didn't set a quit date. He simply lost interest. It happen…

AI Summary: A large observational analysis suggests GLP‑1 receptor agonists — the headline-grabbing diabetes and weight-loss drugs — are linked to reduced risk of developing and dying from substance use disorders across multiple substances. Researchers urge cautious optimism: signals are intriguing, but causality remains unproven and more controlled trials are needed before rewriting addiction treatment playbooks.